Atlas Trials

A Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With Schizophrenia

Clinical trial NCT03356639 · COMPLETED

Trial details

NCT number
NCT03356639
Sponsor
Astellas Pharma Global Development, Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Schizophrenia
Start date
2018-01-22
Primary completion
2018-05-30
Enrollment
32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.